NCT04692831Active, not recruitingPhase 1
Testing a New Imaging Agent to Identify Cancer
Imaging of HER2-expressing Cancer With Site-Specifically Labeled 89Zr-ss-Pertuzumab
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 30 Dec 2020
- Start date
- 30 Nov 2020
- Primary completion date
- 30 Nov 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Metastatic breast cancer
- NCT number
- NCT04692831
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 60
- From 30 Nov 2020 to the primary completion date, 30 Nov 2027
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Creatinine \> 2 times normal limit (obtained with 8 weeks of enrollment)
- AST/ALT \> 2 times normal limit (obtained with 8 weeks of enrollment)
Other
- Life expectancy \< 3 months
- Pregnancy or lactation
- Patients who cannot undergo PET/CT due to weight limits (over 450 pounds)
Who the study is looking for
- Biopsy proven HER2-positive or HER2-low primary malignancy or metastatic disease
- Note: HER2 positivity is defined according to American Society of Clinical Oncology guidelines or ERBB2 amplification on next generation sequencing Note: HER2-low is defined as low HER2 expression, with immunohistochemistry (IHC) 1+ or IHC 2+ and in situ hybridization \[ISH\]-negative, including FISH.
- Biopsy proven primary malignancy or metastatic disease
- At least one malignant lesion on CT, MR, or FDG PET/CT within 60 days of protocol enrollment
- Age 18 years or greater
- ECOG performance of 0-2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) Coordinator of this site? Confirm its status | Basking Ridge | United States | Unknown status |
| Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) Coordinator of this site? Confirm its status | Commack | United States | Unknown status |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) Coordinator of this site? Confirm its status | Harrison | United States | Unknown status |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Coordinator of this site? Confirm its status | Middletown | United States | Unknown status |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) Coordinator of this site? Confirm its status | Montvale | United States | Unknown status |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Memorial Sloan Kettering Nassau (Limited Protocol Activites) Coordinator of this site? Confirm its status | Rockville Centre | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.